Method for regulating RAD54B gene expression
By verifying the targeted regulation relationship between hsa-miR-206 and RAD54B, the problem of regulation of RAD54B gene expression was solved, providing a new target for the treatment and diagnosis of triple-negative breast cancer, and laying the foundation for further research.
Patent Information
- Application Number
- CN202411436767.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-26
AI Technical Summary
The specific molecular biological mechanism of the RAD54B gene in triple-negative breast cancer has not been fully elucidated, and the prior art is difficult to effectively regulate its expression, which affects the targeted therapeutic effect of tumor treatment.
By determining the targeted regulatory relationship between hsa-miR-206 and RAD54B gene, bioinformatics software predicts binding sites, constructing a dual luciferase reporter vector, performing cell transfection and Luciferase detection, verifying hsa-miR-206 Regulatory effect on RAD54B expression.
The targeted regulatory relationship between hsa-miR-206 and RAD54B was clarified, laying the experimental foundation for further studying the molecular mechanism of triple-negative breast cancer and providing potential therapeutic targets.
Smart Images

Figure CN119020414A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a method for regulating the expression of RAD54B gene. Background Art
[0002] Triple-negative breast cancer (TNBC) is a special subtype of breast cancer. Compared with other types of breast cancer, it is more prone to invasion and metastasis, lacks effective endocrine therapy and targeted therapy, and has a worse prognosis. It has attracted more and more attention from researchers. MicroRNA (miRNA) is a series of small molecule single-stranded RNA widely found in animals and plants, and is closely related to the occurrence and development of tumors. More and more studies have regarded miRNA as a potential site for the diagnosis and treatment of clinical diseases, and it has an increasingly wide range of uses. However, there are still many relationships between genes and miRNAs that need to be continuously verified for biological functions, so that we can learn more about the biological significance of genes.
[0003] Homologous recombination repair (HRR) is the most accurate way to repair DNA damage in mammalian cells, and RAD54B protein is an important component of this pathway. This protein can ensure that damaged DNA is accurately repaired, thereby reducing the occurrence of related diseases or tumors. The RAD54B gene is located in the 8q21.3-q22 region of human chromosomes. Homozygous mutations at highly conserved positions of the RAD54B gene exist in human primary lymphomas and colon cancers, suggesting that RAD54B gene mutations may be involved in the occurrence of tumors. Proteins such as RAD51 and BRCA1 in the HRR pathway are closely related to the occurrence and prognosis of breast and digestive tract tumors. Since the discovery that RAD54B is involved in DSBs repair, scholars have been constantly exploring the relationship between RAD54B and tumor occurrence, development and prognosis. RAD54B copy number variation (amplification and deletion), single nucleotide polymorphism (missense and nonsense) and mRNA expression changes have been detected in at least 12 different types of cancer, including breast cancer, suggesting that changes in the RAD54B gene and protein are associated with tumorigenesis. The mechanism by which RAD54B participates in cancer formation has not been elucidated, but these experimental results suggest that RAD54B may be used as a new target for clinical cancer treatment. Both RAD54B and the miRNA that regulates its function can be used as new targets for disease diagnosis and treatment, but its specific molecular biological mechanism of involvement in triple-negative breast cancer still needs further in-depth study. Summary of the invention
[0004] The purpose of the present invention is to provide a method for regulating RAD54B gene expression, which determines the targeted regulatory relationship between hsa-miR-206 and RAD54B, and lays an experimental foundation for further studying their effects and molecular mechanisms in triple-negative breast cancer.
[0005] In order to achieve the above object, the technical solution of the present invention is as follows:
[0006] The present invention provides a method for regulating the expression of RAD54B gene, which is a method for regulating the expression of RAD54B gene through hsa-miR-206.
[0007] In the above technical solution, the binding site of hsa-miR-206 is position 17-24 of RAD54B 3'UTR sequence.
[0008] In the above technical solution, the method for regulating RAD54B gene expression by hsa-miR-206 specifically includes the following steps:
[0009] Step 1, using bioinformatics software to predict the RAD54B 3'UTR sequence, predicting that hsa-miR-206 can bind to the RAD54B 3'UTR sequence;
[0010] Step 2, constructing the RAD54B dual luciferase reporter vector;
[0011] Step 3, co-transfecting cells with hsa-miR-206 and the plasmid DNA finally extracted in step 2;
[0012] Step 4, performing Lucifersae detection on the co-transfected cells in step 3;
[0013] Step 5: Conduct statistical data analysis.
[0014] In the above technical solution, it is further preferred that: the bioinformatics software in step 1 is TargetScanHuman 7.1 and / or miRDB.
[0015] In the above technical solution, it is further preferred that: step 2 specifically includes the following steps:
[0016] ①, chemically synthesizing the sense strand and antisense strand of the wild-type sequence and the sense strand and antisense strand of the mutant sequence of each binding site of the RAD54B gene, and adding the sticky ends of XhoI and NotI endonucleases to both ends of the sense strand and antisense strand of each sequence, and adding a NotI endonuclease cleavage site to the downstream sequence of the XhoI endonuclease cleavage site;
[0017] ② Dilute the sense and antisense plasmids of the wild-type or mutant sequence of each site by 50 times, take 1 μL of each as a template, mix with 46 μL of annealing buffer, incubate at 68°C for 6 minutes, and then incubate at 37°C for 4 hours to anneal the target gene fragment into a double strand, dilute 10 times for standby use, and then perform PCR amplification;
[0018] ③, Take 15 μL of the PCR product of RAD54B and psiCHECK-2 vector from step ②, digest with XhoI endonuclease and NotI endonuclease respectively, mix well, react at 37℃ for 3h, and recover the linearized vector fragment after 1% gel electrophoresis;
[0019] ④, take 5 μL of the linearized vector fragment recovered in step ③ and 50 μL of DH5α competent cells, place them in an ice bath for 30 min, heat shock them in a 42°C water bath for 90 s, quickly transfer the tubes to an ice bath, place them in an ice bath for 2 min, add 200 μL of LB medium, mix well, and culture them at 37°C, 200 rpm for 60 min;
[0020] ⑤ In a clean bench, evenly spread the bacterial solution from step ④ on LB plates containing ampicillin (Amp) (100 μg / mL) and place at room temperature until the liquid is absorbed; invert the plates and transfer them to a 37°C biochemical incubator for overnight culture; pick several single clones from the plates and culture them in 3 mL LB tubes on a shaker overnight, extract plasmid DNA, and perform XhoI and NotI digestion and sequencing identification.
[0021] In the above technical solution, it is further preferred that: step 3 specifically includes the following steps:
[0022] Cationic liposome method for cell transfection:
[0023] ① One day before transfection, cells were cultured at 2×10 4 100 / well were inoculated on a 24-well plate, and the culture medium was DMEM high glucose containing 10% FBS;
[0024] ② On the day of transfection, when the cell confluence was 50-60%, the old culture medium was removed, the cells were washed twice with PBS, and then 300 μL OPTI-MEM (Invitrogen) culture medium was added to each well and placed in a 5% CO2, 37°C incubator;
[0025] ③ Dilute 1 μL of cellfectin II Reagent (Invitrogen) in OPTI-MEM medium in each well to a final volume of 50 μL and let stand at room temperature for 5 min;
[0026] ④ Add 1 μL of 20 μM hsa-miR-206 or 1 μL of hsa-miR-206 inhibitor (either one is fine) and 0.5 μg of plasmid DNA obtained in step 2 to each well, then add OPTI-MEM to a total volume of 50 μL and let stand at room temperature for 5 min; the final hsa-miR-206 concentration in the incubation solution is 50 nM, and the hsa-miR-206 inhibitor concentration is 100 nM;
[0027] ⑤ The dilutions in the compounding steps ③ and ④ were allowed to stand at room temperature for 20 minutes;
[0028] ⑥Add 100 μL of the transfection complex solution prepared in step ⑤ to each well and shake the 24-well plate to mix;
[0029] ⑦ Incubate in a 5% CO2, 37°C incubator for 5 h, and replace the culture medium containing the transfection complex solution with fresh complete culture medium (containing serum).
[0030] Note: The tips used have been treated with RNase removal.
[0031] In the above technical solution, it is further preferred that step 4 specifically includes the following steps:
[0032] The sample luciferase activity was detected using the Dual-Luciferase Reporter Assay System (E1910) from Promega. The specific steps are as follows:
[0033] 48 h after the cells were co-transfected with hsa-miR-206 and plasmid DNA in step 3, the old culture medium was removed, the cells were washed twice with PBS, 100 μL of PLB (Passive Lysis Buffer) was added to each well of cells, and the cells were gently shaken at room temperature for 15 minutes, and the cell lysate was collected;
[0034] 1. Use a manual dual fluorescence detector (Promega, GloMax bioluminescence detector)
[0035] 1) After adding 20 μL of cell lysate to the luminescent plate, read the background value for 2 seconds using a GloMax bioluminescence detector;
[0036] 2) Add 100 μL of LAR II working solution to each sample, mix quickly, and read the value for 2 seconds;
[0037] 3) After reading, add 100 μL Stop & Reagent, after quick mixing, put into the luminescence detector and read the value for 2 seconds;
[0038] 4) Save data;
[0039] 5) Analysis of test results
[0040] The fluorescence intensity of firefly luciferase is F;
[0041] The fluorescence intensity of Renilla luciferase is R;
[0042] △Activity multiple = (R / F) sample / (R / F) control.
[0043] In the above technical solution, it is further preferred that: step 5 specifically includes the following steps:
[0044] The experiment was repeated three times independently, and the data were expressed as x±s. SPSS17.0 statistical software was used for data analysis, and the means between the two groups were compared with T test. The difference was considered statistically significant when P<0.05.
[0045] The beneficial effects of the present invention are:
[0046] The present invention determines the targeted regulatory relationship between hsa-miR-206 and RAD54B, laying an experimental foundation for further studying their effects and molecular mechanisms in triple-negative breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] The present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments.
[0048] Figure 1 This is the sequencing peak diagram of the hsa-miR-206 core binding site (Position 17-24 of RAD54B 3'UTR).
[0049] Figure 2 This is the sequencing peak diagram after the hsa-miR-206 core binding site (Position 17-24 of RAD54B 3'UTR) mutation.
[0050] Figure 3 This is a graph showing the luciferase expression activity at each binding site after co-transfection of RAD54B and hsa-miR-206.
[0051] Figure 4 This is a comparison chart of the activities of each group of plasmids transfected with cloned RAD54B gene 3'UTR.
[0052] Figure 5 This is a comparison chart of the activities of each group of plasmids transfected with cloned mutRAD54B gene 3'UTR.
[0053] Figure 6This is the electrophoresis pattern of PCR product gel recovery during the construction of the wild-type dual-reporter vector; wherein, lane M2: 1kb DNA Marker; lane 1: RAD54B PCR amplification product (210bp); lane M1: DL2000 DNA Marker.
[0054] Figure 7 This is the electrophoresis pattern of the plasmid extracted for enzyme digestion identification during the construction of the wild-type dual-reporter vector; wherein, lane M2: 1kb DNA Marker; lane 1: plasmid digestion product of RAD54B-1; lane 2: plasmid digestion product of RAD54B-2; lane 3: plasmid digestion product of RAD54B-3; lane M1: DL 2000 DNA Marker. DETAILED DESCRIPTION
[0055] The present invention provides a method for regulating RAD54B gene expression, determines the targeted regulatory relationship between hsa-miR-206 and RAD54B, and lays an experimental foundation for further studying their effects and molecular mechanisms in triple-negative breast cancer.
[0056] In view of the important role of RAD54B in the occurrence and development of tumors, the present invention uses the firefly / Renilla dual luciferase reporter system for target verification to determine whether there is a definite target relationship between hsa-miR-206 and the RAD54B gene.
[0057] 1. Materials and methods
[0058] 1.1 Prediction of RAD54B 3'UTR sequence using bioinformatics software:
[0059] Using three microRNA prediction softwares, TargetScan Human 7.1, miRanda, and miRDB, it was predicted that hsa-miR-206 could bind to RAD54B 3'UTR.
[0060] The prediction results are shown in the following table:
[0061]
[0062] 1.2 Construction of dual luciferase reporter vector
[0063] ①, chemically synthesizing the sense strand and antisense strand of the wild-type sequence and the sense strand and antisense strand of the mutant sequence of each binding site of the RAD54B gene, and adding the sticky ends of XhoI and NotI endonucleases to both ends of the sense strand and antisense strand of each sequence, and adding a NotI endonuclease cleavage site to the downstream sequence of the XhoI endonuclease cleavage site;
[0064] The step ① comprises synthesizing the sense strand and antisense strand of the wild-type sequence and the sense strand and antisense strand of the mutant sequence of each binding site of the RAD54B gene; then adding the sticky end of XhoI endonuclease to one end of the sense strand of each sequence and the sticky end of NotI endonuclease to the other end, adding the sticky end of XhoI endonuclease to one end of the antisense strand and the sticky end of NotI endonuclease to the other end, and adding NotI endonuclease cleavage sites to the downstream sequences of the XhoI endonuclease cleavage sites of the sense strand and the antisense strand;
[0065] ② Dilute the sense and antisense plasmids of the wild-type or mutant sequence of each site 50 times, take 1 μL of each as a template, mix with 46 μL of annealing buffer, incubate at 68°C for 6 minutes, and then incubate at 37°C for 4 hours to anneal the target gene fragment into a double strand, dilute 10 times for later use, and then perform PCR amplification.
[0066] ③ Take 15 μL of the RAD54B PCR product recovered from step ② and psiCHECK-2 vector, digest them with XhoI endonuclease and NotI endonuclease respectively, mix well, and react at 37°C for 3 hours. After 1% gel electrophoresis, recover the linearized vector fragment.
[0067] ④ Take 5 μL of the linearized vector fragment recovered in step ③ and 50 μL of DH5α competent cells and place them on ice for 30 min. Heat shock them in a 42°C water bath for 90 s. Quickly transfer the tube to an ice bath and place them on ice for 2 min. Add 200 μL of LB medium respectively, mix well, and culture them at 37°C and 200 rpm for 60 min.
[0068] ⑤ In a clean bench, evenly spread the bacterial solution from step ④ on an LB plate containing ampicillin (Amp) (100 μg / mL) and place at room temperature until the liquid is absorbed. Invert the plate and transfer it to a 37°C biochemical incubator for overnight culture. Pick several single clones from the plate and culture them overnight in a 3mL LB tube on a shaker, extract plasmid DNA, and perform XhoI and NotI digestion and sequencing identification respectively.
[0069] Part I: Construction of wild-type dual reporter vector
[0070] 1. RAD54B 3'UTR sequence, see NCBI database (NCBI Reference Sequence: NM_012415.3) for details. One binding site in the sequence is:
[0071] Position 17-24 of RAD54B 3'UTR: ACATTCC;
[0072] 2. Amplification primer sequence: (Suzhou Shanghai Biotech Synthetic PAGE Purified 2OD):
[0073] RAD54BXhoIF:
[0074] 5'CCGCTCGAGTGAAAGATTACTTCTGACATTCCATTGCTC 3';
[0075] RAD54BNotIR:
[0076] 5'ATAAGAATGCGGCCGCTACAATGATATAAGCACATCTTTATT 3';
[0077] 3. PCR to obtain genes:
[0078] 1> Template cDNA preparation
[0079] 1. Total RNA extraction
[0080] 1) Collect human cells by centrifugation, add 1 mL of Trizol (Invitrogen) solution, mix by pipetting to fully lyse the cells, and let stand for 5 min;
[0081] 2) Add 200 μL of chloroform, shake vigorously for 30 seconds to allow the aqueous phase and organic phase to fully contact, and let stand at room temperature for 15 minutes;
[0082] 3) Centrifuge at 10,000 g for 15 min at 4°C. The tube can be separated into three layers. RNA is in the upper aqueous phase. Transfer the mixture to another new RNase free EP tube.
[0083] 4) Precipitate RNA: Add 0.5 mL of isopropanol, mix gently and thoroughly, and let stand at room temperature for 10 minutes;
[0084] 5) Centrifuge at 10,000 g for 10 min at 4°C to collect RNA precipitate and discard supernatant;
[0085] 6) Wash twice with 75% ethanol and air dry in a clean bench;
[0086] 7) Add 15-50 μL DEPC water to dissolve the precipitate.
[0087] 2. Total RNA purity and integrity testing
[0088] 1) Purity test: Take 1 μL RNA sample and dilute it 50 times.
[0089] The OD value was measured on a 520UV / Vis Spectrophotometer. The result showed that OD260 / OD 280 The ratio is greater than 1.8, indicating that the prepared RNA is relatively pure and has no protein contamination.
[0090] 2) Total RNA integrity test: Take 1 μL of RNA sample, perform 1% agarose gel electrophoresis at 80V×20min, and use gel imaging system to observe the 5s rRNA, 18s rRNA and 28s rRNA bands of total RNA after EB staining for 10min. The integrity of the three bands proves that the total RNA extraction is relatively complete.
[0091] 3. Reverse Transcription
[0092] 1) Prepare the following solutions in an RNase free PCR tube.
[0093]
[0094] 2) Pour the above solution evenly and keep it at 65℃ for 5 minutes to denature the RNA. Then immediately cool it on ice to prevent RNA renaturation;
[0095] 3) Add the following reagents (Promega) to the PCR tube:
[0096]
[0097] 4) The above 20 μL reaction solution was kept at 30°C for 10 min;
[0098] 5) Keep at 42°C for 60 min;
[0099] 6) Keep warm at 72℃ for 10min.
[0100] 7) Store at -20°C.
[0101] 2>PCR reaction system
[0102] Prepare the following system in a 0.2mL EP tube. Dilute the cDNA template stock solution 20 times and take 0.5μL to amplify RAD54B:
[0103]
[0104] 3> Amplification conditions
[0105] After mixing, the mixture was placed in GeneAmp PCR System 2400 PCR amplification instrument for amplification.
[0106] Amplification conditions of RAD54B gene:
[0107]
[0108] 4>PCR product recovery (DNA gel recovery kit, DONGSHENG BIOTECH)
[0109] 8) After 1% gel electrophoresis of the PCR product, cut the gel band containing the target gene fragment into a clean 1.5 mL EP tube with a scalpel under ultraviolet light. After weighing, add solution BD to the centrifuge tube at a ratio of 100 mg gel to 100 μL solution BD.
[0110] 9) Place in a 60°C water bath for 10 min until the gel is completely dissolved. Shake and mix three times during the water bath.
[0111] 10) Transfer the solution to a DNA purification column, let stand for 2 minutes, centrifuge at 12,000 rpm for 1 minute at room temperature, and discard the filtrate.
[0112] 11) Add 500 μL of solution PE to the column, centrifuge at 12,000 rpm for 1 min at room temperature, and discard the filtrate.
[0113] 12) Repeat the previous operation once.
[0114] 13) Centrifuge the empty column at 12,000 rpm for 1 min at room temperature to completely remove the residual liquid in the purification column.
[0115] 14) Place the column on a new 1.5 mL EP tube, add 30 μL of sterile water preheated at 60°C to the center of the column, and centrifuge at 13400 g for 1 min to elute the DNA.
[0116] 5>PCR product gel excision recovery
[0117] See the photo of PCR product gel recovery for details. Figure 6 ,Depend on Figure 6 The analysis showed that RAD54B was amplified using human cDNA template, and the size was consistent with the prediction (the amplified band was approximately a little above Marker 210bp), proving that the RAD54B target gene had been amplified.
[0118] 4. PCR recovery product and vector double enzyme digestion
[0119] In two sterile 0.2mL EP reaction tubes, take 15μL of RAD54B PCR recovery product and psiCHECK-2 vector respectively, and double-digest with XhoI / NotI. The enzyme digestion system is as follows:
[0120]
[0121] After mixing, react at 37°C for about 3 hours.
[0122] 5. Recovery of enzyme digestion products (DNA gel recovery kit, DONGSHENG BIOTECH)
[0123] 1) After the digestion product is subjected to 1% gel electrophoresis, under ultraviolet light, use a scalpel to cut the gel bands containing the target fragment and the vector into a clean 1.5 mL EP tube, and add solution BD to the centrifuge tube at a ratio of 100 mg gel to 100 μL solution BD.
[0124] 2) Place in a 60°C water bath for 10 min until the gel is completely dissolved. Shake and mix three times during the water bath.
[0125] 3) Transfer the solution to a DNA purification column, let stand for 2 minutes, centrifuge at 12,000 rpm for 1 minute at room temperature, and discard the filtrate.
[0126] 4) Add 500 μL of solution PE to the column, centrifuge at 12,000 rpm for 1 min at room temperature, and discard the filtrate.
[0127] 5) Repeat the previous operation once.
[0128] 6) Centrifuge the empty column at 12,000 rpm for 1 min to completely remove the residual liquid in the purification column.
[0129] 7) Place the column on a new 1.5 mL EP tube, add 30 μL of sterile water preheated at 60°C to the center of the column, and centrifuge at 13400 g for 1 min to elute the DNA.
[0130] 6. Connect the target segment to the vector:
[0131] Add the following reagents to a 0.2 mL EP tube (T4 DNA Ligase enzyme purchased from TaKaRa, catalog number: D2011A;)
[0132]
[0133] Connect at 16°C for 1 h.
[0134] 7. Transformation of ligation products
[0135] 1) Add 5 μL of ligation product to 50 μL of DH5α competent cells in an ice bath. Gently rotate to mix and place on ice for 30 minutes.
[0136] 2) Heat shock in 42℃ water bath for 90s.
[0137] 3) Quickly transfer the tube to an ice bath and incubate for 2 minutes.
[0138] 4) Add 200 μL LB medium respectively, mix well, and culture at 37°C and 200 rpm with shaking for 1 h.
[0139] 5) In a clean bench, spread the bacterial solution evenly on an LB plate containing ampicillin (Amp) (100 μg / mL) and leave it at room temperature until the liquid is absorbed.
[0140] 6) Invert the plate and transfer it to a 37°C biochemical incubator for overnight culture.
[0141] 8. Identification of positive clones by plasmid digestion
[0142] 1>Pick several single clones from the plate and culture them in a 3mL LB tube on a shaking platform overnight;
[0143] 2>Plasmid extraction, (high-purity plasmid small-volume extraction kit, G-SHUN)
[0144] a) Collect 3 μL of bacterial solution in a 1.5 mL EP tube, centrifuge at 12 000 rpm for 1 min, and discard the supernatant.
[0145] b) Add 250 μL of Solution I / RNase A mixture to resuspend the cells.
[0146] c) Add 250 μL of Solution II, mix by gentle inversion for 6 times, and leave at room temperature for 2 min.
[0147] d) Add 350 μL of solution III and mix by gentle inversion for 6 times. (Note: Solution I: 50 mM glucose / 10 mM EDTA / 25 mM Tris-HCl, pH = 8.0, i.e. resuspension solution. Solution II: 0.2 Ml NaOH / 1% SDS, i.e. lysis solution. Solution III: 3 Ml potassium acetate / 2 Ml acetic acid, i.e. neutralization precipitation solution.)
[0148] e) Centrifuge at 12,000 rpm for 10 min, carefully remove the supernatant and transfer it to a DNA purification column, and let it stand for 2 min.
[0149] f) Centrifuge at 12 000 rpm for 1 min and discard the filtrate.
[0150] g) Add 500 μL of solution PB to the column, centrifuge at 12 000 rpm for 1 min, and discard the filtrate.
[0151] h) Add 500 μL of solution W to the column, centrifuge at 12,000 rpm for 1 min, discard the filtrate, and repeat once.
[0152] i) Centrifuge the empty column at 12 000 rpm for 3 min.
[0153] j) Take out the column and place it in a new 1.5 mL EP tube, add 50 μL of sterile water (preheated at 60°C),
[0154] After standing for 2 min, centrifuge at 13,400 rpm for 1 min to elute the plasmid.
[0155] Solution PB is a plasmid extraction reagent purchased from DONGSHENG BIOTECH. Solution PB contains alkali and protein denaturants. Do not contact the skin directly. Solution W is a plasmid extraction reagent purchased from DONGSHENG BIOTECH. Solution W should be diluted with anhydrous ethanol at a ratio of 1:1.5 before first use, i.e., it contains 60% ethanol. Solution BD is a DNA gel recovery reagent purchased from DONGSHENG BIOTECH. Solution BD contains a denaturant. Do not contact the skin directly. Solution PE and Solution BD are a kit purchased from DONGSHENG BIOTECH. Solution PE should be diluted with anhydrous ethanol at a ratio of 1:4 before first use, i.e., it contains 80% ethanol.
[0156] 3> Enzyme digestion and identification of extracted plasmid
[0157] The enzyme digestion reaction system is as follows:
[0158]
[0159] Enzyme digestion at 37℃ for 2h.
[0160] The digestion products were separated by 1% agarose gel electrophoresis containing ethidium bromide (EB) and imaged by UVP gel imaging system. The electrophoresis diagram is shown in Figure 7 .Depend on Figure 7 The analysis showed that RAD54B (210 bp) cut out a target band at the corresponding position, indicating that a positive clone was screened.
[0161] 4>Sequencing and identification of extracted plasmids
[0162] The RAD54B positive plasmid was sent to Shanghai Bio-Gene Co., Ltd. for sequencing. The sequencing results are shown in Figure 1 The sequencing results showed that the wild-type luciferase reporter vectors with one binding site were successfully constructed.
[0163] Part II: Mutation prediction and Hsa-miR-206(17-24) binding site vector construction
[0164] 1. RAD54B 3'UTR sequence:
[0165] The region to be mutated is: Position 17-24of RAD54B 3'UTR: ACATTCC;
[0166] The sequence after mutation is: CTCGGTT;
[0167] 2. Amplification primer sequence: (Suzhou Shanghai Biotech Synthetic PAGE Purified 2OD):
[0168] mutRAD54B-F:
[0169] 5'TGAAAGATTACTTCTGCTCGGTTATTGCTCTTCTTTTGAAAATTAGTA TGGTAATT 3';
[0170] mutRAD54B-R:
[0171] 5'AAGTACATTTAATTACCATACTAATTTTCAAAAGAAGAGCAATAACC GAGCAGAAG 3';
[0172] 3. Gene mutation:
[0173] 1>PCR reaction system
[0174] The following system was prepared in a 0.2 mL PCR reaction tube. The template was the constructed RAD54B plasmid. After the plasmid was diluted 50 times, 1 μL was taken as the template:
[0175]
[0176] 2> Amplification conditions
[0177] After mixing, the mixture was placed in GeneAmp PCR System 2400 PCR amplification instrument for amplification.
[0178] Amplification conditions of mutRAD54B gene:
[0179]
[0180] 3> PCR product was digested with DpnI (to digest the methylated template DNA);
[0181] Add 1 μL of DpnI enzyme (produced by Promega, catalog number: R6231) to the PCR tube and digest at 37° C. for 4 h.
[0182] 4>Transformation of DpnI-treated PCR products, the steps are the same as step 7 in part 1.
[0183] 5>Pick one colony to extract the plasmid, following the same steps as step 8 in part 1.
[0184] 6> Send the samples to Shanghai Bio-Gene Co., Ltd. for sequencing. The sequencing results are shown in Figure 2 .Depend on Figure 2 It can be seen that the mutation predicted Hsa-miR-206 (17-24) binding site vector was successfully constructed.
[0185] 1.3. Co-transfect cells with hsa-miR-206 and plasmid DNA extracted in step 1.2
[0186] Cationic liposome method for cell transfection:
[0187] ① One day before transfection, cells were cultured at 2×10 4 100 / well were inoculated on a 24-well plate, and the culture medium was DMEM high glucose containing 10% FBS;
[0188] ② On the day of transfection, when the cell confluence was about 50-60%, the old culture medium was removed, the cells were washed twice with PBS, and then 300 μL OPTI-MEM (Invitrogen) culture medium was added to each well and placed in a 5% CO2, 37°C incubator;
[0189] ③ Dilute 1 μL of cellfectin II Reagent (Invitrogen) in OPTI-MEM medium in each well to a final volume of 50 μL and let stand at room temperature for 5 min;
[0190] ④ Each well was added with 1 μL of 20 μM hsa-miR-206 or 1 μL of hsa-miR-206 inhibitor and 0.5 μg of plasmid, and then OPTI-MEM was added to a total volume of 50 μL, and incubated at room temperature for 5 min; (the final concentration of hsa-miR-206 in the incubation solution was 50 nM, and the concentration of hsa-miR-206 inhibitor was 100 nM);
[0191] ⑤ The dilutions in the compounding steps ③ and ④ were allowed to stand at room temperature for 20 minutes;
[0192] ⑥Add 100 μL of the transfection complex solution prepared in step ⑤ to each well and shake the 24-well plate to mix slightly;
[0193] ⑦ Incubate in a 5% CO2, 37°C incubator for 5 h, and replace the culture medium containing the transfection complex with fresh complete culture medium (containing serum).
[0194] Note: The tips used have been treated with RNase removal.
[0195] Cell transfection test group settings (each group of data has 3 replicate wells)
[0196]
[0197]
[0198] 1.4. Lucifersae detection
[0199] The sample luciferase activity was detected using the Dual-Luciferase Reporter Assay System (E1910) of Promega. 48 hours after the cells were co-transfected with hsa-miR-206 and plasmid DNA in step 3, the old culture medium was removed, and the cells were washed twice with PBS. 100 μL of PLB (Passive Lysis Buffer) was added to each well of cells, and the cells were gently shaken at room temperature for 15 minutes, and the cell lysate was collected.
[0200] 1. Use a manual dual fluorescence detector (Promega, GloMax bioluminescence detector)
[0201] 1) After adding 20 μL of cell lysate to the luminescent plate, read the background value for 2 seconds using a GloMax bioluminescence detector;
[0202] 2) Add 100 μL of LAR II working solution to each sample, mix quickly, and read the value for 2 seconds;
[0203] 3) After reading, add 100 μL Stop & Reagent, after quick mixing, put into the luminescence detector and read the value for 2 seconds;
[0204] 4) Save data;
[0205] 5) Analysis of test results
[0206] The fluorescence intensity of firefly luciferase is F;
[0207] The fluorescence intensity of Renilla luciferase is R;
[0208] △Activity multiple = (R / F) sample / (R / F) control.
[0209] 1.5 Statistical methods
[0210] The experiment was repeated three times independently, and the data were expressed as x±s. SPSS17.0 statistical software was used for data analysis, and the mean comparison between the two groups was performed using T test, with P < 0.05 as statistically significant.
[0211] 2. Results
[0212] 2.1 Sequencing analysis of luciferase reporter vector
[0213] The vectors containing the wild-type and mutant sequences of the hsa-miR-206 binding site were sequenced, and the results showed that both the wild-type and mutant luciferase reporter vectors of one binding site were successfully constructed ( Figure 1-Figure 2 ).
[0214] 2.2 Luciferase activity assay
[0215] Figure 3 The figure shows the luciferase expression activity of the RAD54B and hsa-miR-206 co-transfection binding site. Figure 3 The analysis showed that the luciferase activity fold of co-transfection of 3'UTR RAD54B and hsa-miR-206 was 50%; the relative value of luciferase activity fold of the hsa-miR-206 core binding site predicted by mutation was 101%, indicating that hsa-miR-206 can target and regulate its expression by binding to 3'UTR RAD54B, and there is only one binding site.
[0216] Figure 4 This is a comparison chart of the activities of each group of transfected cloned RAD54B gene 3'UTR plasmid. Figure 4 The analysis showed that in the experiment of transfecting the plasmid with 3'UTR RAD54B, the difference between the mir group and the blank group was **P<0.01 (P=0.0007), and the difference between the mir group and the NC group was **P<0.01 (P=0.0004), indicating that hsa-miR-206 can affect the fluorescence activity of 3'UTR RAD54B by binding to it. The difference between the hsa-miR-206inhibitor group and the blank group was **P<0.01 (P=0.0093), and the difference between the hsa-miR-206inhibitor group and the NC inhibitor group was *P<0.05 (P=0.0121), indicating that the exogenous hsa-miR-206inhibitor inhibited the endogenous hsa-miR-206 in HEK-293T cells, resulting in a significant increase in activity compared with Blank / NC inhibitor.
[0217] Figure 5 This is a comparison chart of the activities of each group of transfected cloned mutRAD54B gene 3'UTR plasmid. Figure 5The analysis showed that in the experiment of transfecting clones with mut3'UTR RAD54B plasmid, there was no statistical difference between the mir group and the blank group (P=0.8896), and there was no statistical difference between the mir group and the NC group (P=0.9384), indicating that hsa-miR-206 could not affect the change of its fluorescence activity by binding to mut3'UTR RAD54B. There was no statistical difference between the hsa-miR-206 inhibitor group and the blank group (P=0.8445), and there was no statistical difference between the hsa-miR-206 inhibitor group and the NC inhibitor group (P=0.7954). This shows that the hsa-miR-206 binding site has been completely mutated, resulting in no significant difference in the activity of the added hsa-miR-206 mimics.
[0218] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A method for regulating RAD54B gene expression, characterized in that: This method is a method for regulating RAD54B gene expression through hsa-miR-206.
2. The method for regulating RAD54B gene expression according to claim 1, characterized in that: The binding site of hsa-miR-206 is the 17th to 24th position of the RAD54B 3'UTR sequence.
3. The method for regulating RAD54B gene expression according to claim 1, characterized in that: The specific steps include: Step 1, using bioinformatics software to predict the RAD54B 3'UTR sequence, predicting that hsa-miR-206 can bind to the RAD54B 3'UTR sequence; Step 2, constructing the RAD54B dual luciferase reporter vector; Step 3, co-transfecting cells with hsa-miR-206 and the plasmid DNA finally extracted in step 2; Step 4, performing Lucifersae detection on the co-transfected cells in step 3; Step 5: Conduct statistical data analysis.
4. The method for regulating RAD54B gene expression according to claim 3, characterized in that: The bioinformatics software in step 1 is TargetScan Human 7.1 and / or miRDB.
5. The method for regulating RAD54B gene expression according to claim 3, characterized in that: In step 3, cationic liposome method is used for cell transfection.
6. The method for regulating RAD54B gene expression according to claim 3, characterized in that: In step 4, the luciferase activity of the sample is detected using the Dual-Luciferase Reporter Assay System of Promega.
7. The method for regulating RAD54B gene expression according to claim 3, characterized in that: Step 5 specifically includes the following steps: The experiment was repeated three times independently, and the data were expressed as x±s. SPSS17.0 statistical software was used for data analysis, and the means between the two groups were compared with T test. The difference was considered statistically significant when P<0.05.
